ReviewJugan geon-gang gwa jilbyeong2025
HIV Treatment Paradigm Shifts over the Past 40 Years.
Review in Jugan geon-gang gwa jilbyeong, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Design, Synthesis, In Silico Studies, and HIV-1 RT Inhibitory Activity of 1,3-Oxazolidine Pyrimidine Nucleoside Analogues.Chemistry & biodiversity · 2026Article
- Article
- Commemoration of the Special Issue on HIV/AIDS in "Jugan geon-gang gwa jilbyeong · 2025Article
- HIV/AIDS Management Programs in Republic of Korea: Achievements and Future Direction.Jugan geon-gang gwa jilbyeong · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This review summarizes the evolution of human immunodeficiency virus (HIV) treatment over the past 40 years, tracing its transition from a fatal infectious disease to a chronic condition and outlining current therapeutic trends that characterize the paradigm shift in care. Methods: Key milestones in HIV therapy were examined through a narrative review, beginning with the introduction of zidovudine in 1987 and extending to highly active antiretroviral therapy (HAART) and recent long-acting injectable agents. Results: The adoption of triple-drug HAART in 1996 addressed the resistance challenges of monotherapy and substantially reduced HIV-related morbidity and mortality. Since the mid-2010s, integrase strand transfer inhibitor (INSTI)-based single-tablet regimens have delivered potent viral suppression, strong resistance barriers, and improved treatment convenience, yielding success rates exceeding 90%. In addition, the implementation of the "Treat All" strategy and the "U=U (Undetectable=Untransmittable)" principle has enhanced individual health and supported broader epidemic control. Conclusions: Current HIV therapy continues to evolve beyond viral suppression toward patient-centered approaches, including two-drug regimens and long-acting injectables, to address unmet needs and enhance quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.